11th Sep 2025 07:00
11 September 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Investor Event and Presentation
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that the Company will be presenting at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Brewery Place, Leeds, LS10 1NE. Event registration opens at 4.30 pm and presentations commence at 5.00 pm.
Nigel Theobald, Chief Executive Officer, will be presenting on the Company's ongoing development of Nuvec® as a delivery system for RNA therapeutics.
For further information on the ShareSoc Growth Company Seminar and registration, please visit the event website: https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-person-event-leeds/
A link to N4 Pharma's presentation will be made available on the Company website following the event. No new material information will be disclosed at this event.
- Ends -
For more information please contact:
N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub |
Via N4 Pharma Investor Hub: investors.n4pharma.com
https://n4pharma.com/link/eY2Bqr.
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44 (0)20 3657 0050 |
Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0)113 730 3896
|
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.
Related Shares:
N4 Pharma Plc